BTKi - a class of drugs (Bruton's tyrosine kinase inhibitors)

BTKi ???

"I'm from Kansas, no way, Doc, I'm not taking anything named BTK !!!!!"

#Kansas #BTK #BTKi #ForgetAboutIt #NoWayDoc

Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL Most patients with CLL who discontinued BTK inhibitors and later received BCL2i achieved early responses but poor long-term outcomes.

Patients with chronic lymphocytic leukemia (#CLL) who discontinued covalent #BTKi and later required #BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap.

Read here: https://bit.ly/3YkhbQn

#RareDisease #ChronicLymphocyticLeukemia #MedSky

#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg
#HemeSky #OncSky

🚨 HUGE MS breakthrough! Roche's oral BTK inhibitor fenebrutinib nails Phase III:

✅ RMS: 1st BTKi to beat teriflunomide on relapses (96+ wks)
✅ PPMS: Slows disability ≥ ocrelizumab (120+ wks)
✅ Clean safety, brain-penetrant

#MultipleSclerosis #MS #BTKi #Roche #Neurology

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis | NEJM Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclero...

Phase III trial data for #BTKi tolebrutinib in relapsing #multiplesclerosis and non-relapsing SP-MS out now. FDA decision for #tolebrutinib for SP-MS and disability progression more generally (PIRA) expected in September this year

www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....

Abstract 5️⃣ Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3). Kuter DJ, et al. #ITP #BTKi bit.ly/3V13XXz